GCAN · The Greater Cannabis Company, Inc.

The Greater Cannabis Company's FY2025 financial results reflect ongoing pre-revenue challenges in its cannabinoid development efforts. Operating income was -$183.0K, a 17.1% worsening from -$156.3K in FY2024, driven by operating expenses of $183,005 versus $156,276 last year. Management's Item 7 discussion emphasizes that these expenses represent historical costs, which understate true economic impact because they exclude replacement costs or inflation adjustments. Actual net operating losses would be larger under such measures, underscoring the distortive effect of not reflecting current pricing realities in a high-inflation environment for specialized cannabinoid operations.

Net income deteriorated to -$331.6K from -$179.0K, an 85.2% deeper loss on a relative basis. With cost of sales at $0 for both years, the absence of revenue left the company fully exposed to expense pressures. Diluted EPS held flat at $0.00 year-over-year, signaling persistent per-share losses without dilution from new issuances detailed in the statements. This core unprofitability stems from the company's developmental stage, where Item 1 notes that despite launching a product and securing limited initial orders, management elected to pursue alternative opportunities offering superior growth and profitability prospects.

Management commentary in Item 7 highlights inherent uncertainties in estimating future outcomes, with judgments growing more subjective as variables multiply. The strategic pivot away from the initial product—prompted by its limited traction—positions the company to chase higher-potential licensing or development paths, but low cash constrains near-term progress. Investors should note that historical cost reporting masks inflation's toll on expenses, potentially understating the capital intensity of cannabinoid R&D amid shifting regulatory and market dynamics. Future viability hinges on securing capital to operationalize these opportunities while navigating going-concern pressures from recurring losses.